ArticleCureus2025
A Case of Post-transplant Lymphoproliferative Disorder After Successful Treatment of Islet Transplantation Without Graft Rejection.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a lymphoid or plasmacytic proliferation that occurs in association with immunosuppression and is recognized as a relatively rare but serious complication following solid organ transplantation; however, PTLD following islet transplantation is extremely rare, and its optimal management remains unclear. We report the case of a 55-year-old woman with a history of type 1 diabetes mellitus who underwent living-donor kidney transplantation followed by deceased-donor pancreas transplantation and subsequently received three islet transplantations due to recurrent diabetes. Five years after the final islet transplantation, she developed persistent fever, and fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) revealed small intestinal wall thickening and lymphadenopathy in the mesentery and axilla. A biopsy confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL)-type PTLD. Immunosuppressive therapy was carefully adjusted without complete discontinuation, and initial treatment with four cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) achieved partial remission. This was followed by four cycles of DA-EPOCH-R (dose-adjusted toposide, prednisone, vincristine, cyclophosphamide, hydroxydaunorubicin, and rituximab), which led to complete remission of PTLD. Notably, islet graft function was preserved throughout treatment, and no recurrence of PTLD was observed during follow-up. To our knowledge, this is the first reported case of PTLD following islet transplantation in Japan, and it highlights the potential for achieving remission with preserved graft function through careful immunosuppressive adjustment and appropriate chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.